Objetivo Approximately 10% of the global population (40% of people over 65), suffers hearing difficulties. The socio-economic impact is deep, since in children, early hearing impairment (HI) affects language learning, and in adults, acquired HI impairs social integration. The sense of hearing depends upon the integrity of the sensory epithelia in the inner ear. HI occurs when this tissue is disrupted, that is when the sensory hair cells (HC) die and the spiral ganglion neurons (SGN) subsequently degenerate and die. To date, there is no potent curative or preventive solution for HI, the clinical options are based on the use of prostheses such as cochlear implants. Studies are being conducted to develop alternative treatments combining both preventive and reparative strategies. Since HC and SGN are of the same developmental origin, transcription and growth factors that modulate early development of the inner ear have been under the scope. These studies gave rise to two main therapeutic hypotheses, the use of exogenous stem cell with induction of their differentiation to HC and/or SGN, or the proliferation/transdifferentiation of cells supporting HC in the inner ear. Up to now, problems of cell death and control of the cell differentiation have slowed down the emergence of new therapies.To address this problem, AFHELO projects plans to evaluate potency of AF243, a small molecule which is a strong inducer of cell differentiation with interesting potencial on carcino-embryonic cells differentiation and neuron survival, and on an in vivo model of chemo-induced deafness, used for cochlear implant testing.The strategy is to optimize AF243 development by first extending the therapeutic applications to two major types of HI (noise-induced and age related/presbycusis) and second by completing the preclinical studies (pharmacology, mechanism of action, ADME, safety) supporting the clinical evaluation of AF243 for prevention and/or treatment of sensorineural HI. Ámbito científico medical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesmedical biotechnologyimplantsmedical and health sciencesbasic medicinepharmacology and pharmacy Programa(s) FP7-HEALTH - Specific Programme "Cooperation": Health Tema(s) HEALTH.2012.2.4.5-1 - Technological approaches to combating sensory impairments Convocatoria de propuestas FP7-HEALTH-2012-INNOVATION-2 Consulte otros proyectos de esta convocatoria Régimen de financiación CP-FP - Small or medium-scale focused research project Coordinador AFFICHEM SA Aportación de la UE € 1 444 971,00 Dirección RUE SAINT JOSEPH 9 31400 TOULOUSE Francia Ver en el mapa Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Frederic Thivet (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos Participantes (2) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo UNIVERSITE DE LIEGE Bélgica Aportación de la UE € 650 400,00 Dirección PLACE DU 20 AOUT 7 4000 Liege Ver en el mapa Región Région wallonne Prov. Liège Arr. Liège Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Isabelle Halleux (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS España Aportación de la UE € 701 005,00 Dirección CALLE SERRANO 117 28006 Madrid Ver en el mapa Región Comunidad de Madrid Comunidad de Madrid Madrid Tipo de actividad Research Organisations Contacto administrativo Antonio Javier Sánchez Herencia (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos
